List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
25 July 2024 | By Eurofins Discovery
Eurofins Discovery’s Luke Oostdyk, PhD, will highlight anti-obesity target combination therapies and cell-based assays ideal for testing functional activity, specificity, potency and signalling mechanisms of desired therapies against multiple disease-relevant targets.
Discover how Cue Biopharma harnesses the curative potential of the body’s intrinsic immune system to develop treatments for oncology and autoimmune diseases. Here, Anish Suri, Chief Scientific Officer of Cue Biopharma, explains how its platforms and biologics are designed to selectively modulate disease-specific T cells to restore immune balance, aiming…
KDR inhibitors could be very impactful for treatment of ATLL and HAM/TSP or prevent disease by lessening the viral load of HTLV-1.
As part of our series highlighting women in STEM, we spoke to Juliet Williams, Head of Research at Kymera. She discusses what inspired her early passion for science, the power of mentorship and what excites her most about the future of targeted protein degradation – and its potential to deliver…
Blocking the TGF-β signalling pathway produced effective antitumour activity against hepatocellular carcinoma.
17 July 2024 | By Eurofins Discovery
Join this webinar to hear from Eurofins Discovery on the latest offerings for drug-drug interaction assessments using CRISPR KO/KI MDCKII cell lines
Researchers show that proteins released from the brain during migraine with aura are transported by CSF to pain-signalling nerves.
At the heart of precision oncology is the need to increase our understanding and knowledge of surface proteins found on tumour cells. Here Roman Thomas, CEO of DISCO Pharmaceuticals, explains how it is using cutting-edge technology to explore the surfaceome – a map of the proteins on the cell’s surface…
Researchers have discovered that pancreatic cancer’s resistance to chemotherapy is related to the physical stiffness of the extracellular matrix.
Understanding how MMR-deficient colorectal cancers drive tumour growth and avoid immune detection could pave the way for personalised cancer medicine.
A new assay has been developed which enables the detailing of intact proviral genomes of under-studied HIV strains.
Researchers found that tumour beta cells lose their repression marks and express elevated levels of oncogenes.
The hiPSC-derived skeletal muscle model is the first to uncover the biological mechanisms underlying loss of mobility.
Researchers have designed synthetic, soluble versions of cell membrane proteins, which will enable faster and easier screening for new drugs.
Mini-colons, which closely resemble in vivo tissue, were used for several applications, including the characterisation of anticancer drug toxicity profiles.
